Added to YB: 2026-05-11
Pitch date: 2026-05-08
CPRX [neutral]
Catalyst Pharmaceuticals, Inc.
+1.09%
current return
Author Info
Action This Day shares edgy, actionable ideas that can be implemented in a day. Sign up for the newsletter.
Company Info
Catalyst Pharmaceuticals, Inc. operates as a biopharmaceutical company engaged in developing and commercializing novel medicines for patients living with rare diseases.
Market Cap
$3.9B
Pitch Price
$31.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
10.13
P/E
18.20
EV/Sales
5.20
Sector
Biotechnology
Category
special_situation
Catalyst Catalyst
CPRX (update): Angelini Pharma acquiring for $31.50/share cash (~$4.1B), 28% premium to 30-day VWAP. Marks Angelini's US entry, combining CPRX's rare disease portfolio (FIRDAPSE for LEMS, AGAMREE for DMD, FYCOMPA antiepileptic) w/ Angelini's Brain Health platform. Settled Hetero Firdapse patent litigation. Close expected Q3 2026.
Read full article (4 min)